Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
Protocol ID
AALL1631
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
New diagnosis
Location
NSW, QLD, WA
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
EsPhALL network I-BFM Study Group
EsPhALL network I-BFM Study Group
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Christchurch Hospital
Starship Hospital
John Hunter Children's Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
1 year to 21 years at diagnosis
International registry ID's
NCT03007147
| Study Title | International Phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones |
|---|---|
| Protocol ID | AALL1631 |
| Disease (Sub Disease) | Leukaemia (ALL) |
| Diagnosis Stage | New diagnosis |
| Location | NSW / QLD / WA |
| Sponsor | Children's Oncology Group |
| Collaborators | National Cancer Institute (NCI)/ EsPhALL network I-BFM Study Group |
| Links | https://clinicaltrials.gov/ct2/show/NCT03007147 |
| Trial Status | Open |
| Trial Open Date | 19/04/2018 |
| Sites | The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital / Christchurch Hospital / Starship Hospital/ John Hunter Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | 1 year to 21 years at diagnosis |
| International registry ID's | NCT03007147 |